Pirtobrutinib approved to treat chronic lymphocytic leukemia and small lymphocytic lymphoma

View at publisher Summarise with VIRAT
Authors: Diane S. Aschenbrenner
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Pirtobrutinib (Jaypirca), a first-generation noncovalent Bruton tyrosine kinase inhibitor, has received approval to treat relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The drug poses risks for several serious adverse effects, including infections, hemorrhage, cytopenias, cardiac arrythmias, and embryo–fetal toxicity. Nurses should teach patients they will need repeated blood work to assess for laboratory abnormalities.

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Acute Lymphoblastic Leukemia research

Publication details

Journal / source
AJN American Journal of Nursing
Volume
126
Issue
4
Pages
24–24
Publication date
26 March 2026
Language
EN